NEWS
April 25, 2012Revalesio to Present New Parkinson’s Data at the American Academy of Neurology “Future of Neuroscience” Conference+
March 6, 2012Rush University Study Demonstrates Neuro-protective and Anti-inflammatory Activity of RNS60+
November 14, 2011Revalesio’s RNS60 Reduces Cardiac Damage in Pig Study of Heart Attacks+
Revalesio Successfully Completes Phase I Intravenous Safety Study of RNS60+
Revalesio is a pioneering biotechnology company based in Tacoma, Washington, dedicated to restoring hope and transforming lives.
Our goal is to maximize the benefits of our novel technology by developing products that represent a potential new class of treatments for inflammatory mediated diseases. To that end, Revalesio has partnered with leaders in biomedical research as well as non-profit organizations around the world to help us deliver on our promise to bring hope to people around the globe.